Remove Patent Remove Patent Application Remove Settlement
article thumbnail

SpicyIP Weekly Review (January 13 – January 19)

SpicyIP

Case Summaries Gilead Sciences Inc vs Union Of India on 19 December, 2024 (Madras High Court) Image from here The writ petition pertains to a patent application filed by the petitioner, which was contested by the 4 th respondent through a post-grant opposition. Macleods Pharmaceuticals Ltd vs The Controller Of Patents & Anr.

article thumbnail

Petitioner Failed to Establish Standing in IPR Appeal

Intellectual Property Law Blog

Cloudbreak Therapeutics, LLC addresses whether an IPR petitioner can assert Article III standing on appeal based on potential infringement liability and potential preclusive effects on its patents. 10,149,820 (the “’820 patent”), which is directed to compositions and methods for treating pterygium. Background Cloudbreak owns U.S.

Marketing 162
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Patent Eligibility Jurisprudence

Patently-O

The USPTO is seeking comments on “the state of patent eligibility jurisprudence” and how eligibility law impacts both innovation and investment-in-innovation. and (2) Is patent eligibility a question of law for the court or a question of fact for the jury? The deadline for submissions is October 15, 2021. Berkheimer, No.

Patent 102
article thumbnail

Special 301 Report 2023: Reflections from Public Health Perspective

SpicyIP

The consistent issues that the US cites for placing India in the Special 301 Report are inter alia, India’s provisions on revocation of patents, oppositions, lack against the presumption of validity, lack of data exclusivity provisions and Section 3(d). India and the US have been at loggerheads over patent issues until recently.

Reporting 137
article thumbnail

USPTO Announces Slate of Proposed Rule Changes

JD Supra Law

On April 20, 2023, the United States Patent and Trademark Office (USPTO) announced several proposed rule changes that would have an impact on patent applicants, patent holders, and patent challengers. By: Proskauer - Minding Your Business

article thumbnail

SpicyIP Weekly Review (August 16 – 22)

SpicyIP

Micro Labs Limited the Delhi High Court granted an ex-parte interim injunction in favour of the plaintiff in a case involving a patent of the compound ‘Apixaban’. The Ministry of Commerce and Industry has announced an 80% reduction in patent application fees for all recognised educational institutions. and held that Google Inc.

article thumbnail

Biosimilar Maker Leverages IPR to Avoid Patent Dance and Obtain Early Market Entry

Bio Law Blog

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. The patents at issue are U.S. Patent Nos.